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The majority of deaths in patients with type 2 diabetes mellitus 
(T2DM) result from accelerated cardiovascular arteriosclerosis.1 The 
mortality attributable to cardiovascular disease (CVD) is increased 
3.2‐fold in men and 8.5‐fold in women with T2DM compared to that 
in people not affected by the disease.1 Macrovascular disease is as‐
sociated with lower degrees of hyperglycaemia than microvascular 
disease.2 The heightened risk for CVD extends to individuals with 
impaired glucose tolerance (IGT).3 Both IGT and impaired fasting 
glucose (IFG) are intermediate states in glucose metabolism and as‐
sociated with increased CVD risk.4
Abdul‐Ghani et al showed conversion rates to T2DM at 2.4%, 
5.1%, 11.5% and 13.5% for individuals with normal glucose tolerance 
(NGT), IFG, IGT or combined glucose tolerance (CGI), respectively, 
over a 7‐ to 8‐year follow‐up period.5 Moreover, they divided NGT 
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Aims: This study aims to assess insulin secretion and resistance through oral glucose 
tolerance	test	(OGTT)	among	young	Japanese	individuals.
Subjects and methods: We enrolled 595 young healthy Japanese individuals aged 
22‐29	years.	They	underwent	an	OGTT,	and	their	results	were	divided	into	4	groups	
(I‐IV), according to the time at which their plasma glucose concentration declined 
below the fasting glucose concentration (30, 60 or 120 minutes or never as groups I, 
II, III and IV, respectively).
Results: We classified 575 normal glucose‐tolerant subjects into 4 groups (I‐IV) 
with I: 28 (4.9%), II: 120 (20.9%), III: 143 (24.9%) and IV: 284 (49.4%) individuals. The 
Matsuda, insulinogenic and disposition indices were decreased from groups I to IV. 
ROC	curves	of	disposition	index	reflecting	the	composition	of	insulin	secretion	and	
sensitivity classified the prolonged glucose elevation group (group III + IV) from the 
rapid glucose lowering group (group II; AUC = 0.847).
Conclusions: Even in a young and healthy Japanese individual within the physiologi‐
cal range of glycaemic control, there is a sequential decrease in insulin sensitivity and 
secretion.
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and IFG subjects into four groups (I‐IV), based upon the time (30, 
60, or 120 minutes or never) at which their plasma glucose concen‐
trations declined below the fasting glucose concentration after the 
oral glucose load. In NGT subjects, the incidence rate for the devel‐
opment of T2DM was 0% in group I and increased progressively to 
1.8%, 2.1% and 2.9% in groups II, III and IV, respectively.5
Analyses	 from	 the	DECODE	 data	 set	 have	 demonstrated	 that	
the hazard ratios for all‐cause mortality in patients with IFG and IGT 
compared with those with normal fasting and 2‐h glucose tolerance 
were 1.20 and 1.50, respectively.6 A number of studies comparing 
IGT to IFG seem to point to IGT as being the better predictor of fu‐
ture T2DM development.7‐9 However, one study demonstrated both 
of them are equivalent.10
Reliable models for the identification of individuals at high‐risk 
of T2DM are essential to improve strategies for the prevention of 
the	 disease.	 The	 oral	 glucose	 tolerance	 test	 (OGTT)	 is	 commonly	
used to identify high‐risk individuals.11	The	OGTT	is	a	useful	exam‐
ination tool, not only for diagnosis of T2DM, but also for estimation 
of insulin secretion. However, due to the need for frequent blood 
samplings, few studies have been done in young subjects who are 
commonly healthy.
In	this	study,	we	obtained	OGTT	results	from	university	students,	
analysed their glucose curves and insulin secretion, and divided the 
subjects into four groups, according to a published protocol.5 We 
also studied lipid profiles and compared with the indices of insulin 




All the participants signed informed consent forms, and the Gunma 
University Ethical Review Board for Medical Research Involving 
Human	 Subjects	 approved	 the	 study	 protocol.	 Participants	 were	
volunteers purely.
The participants were 595 medical candidates who practised at 
the Gunma University Hospital between May 2010 and July 2016. 
No subjects were diagnosed as having T2DM or received any medi‐
cation. As part of their medical practice, they all underwent a com‐
prehensive	medical	examination,	including	an	OGTT	(75	g	dextrose	
monohydrate in 250 mL water) after an overnight fast.
F I G U R E  1   Grouping based on plasma 
glucose (A) and insulin (B) concentrations 
in subjects with normal glucose tolerance 
(NGT) according to the study by Abdul‐
Ghani et al5
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2.2 | Study design
The	OGTTs	were	performed	after	10‐hour	 fasts	with	0‐,	 30‐,	 60‐	
and 120‐minute samplings to establish plasma glucose and insulin 
levels, and at the preload time, serum high‐density lipoprotein cho‐
lesterol (HDL‐C), low‐density lipoprotein cholesterol (LDL‐C), triglyc‐
eride (TG), haemoglobin A1c (HbA1c) and glycoalbumin (GA) were 
measured. Excluded from this study were subjects who were over 
30 years of age.
We classified 575 subjects into the NGT group, 19 into the IGT 
group, and 1 into the IFG group. We removed the subjects with IGT 
and IFG from further analyses in this analysis. We found no subjects 
with apparent T2DM.
We measured height and weight and calculated BMIs (weight 
[kg]/height [m2]). We used enzymatic methods to measure serum 
HDL‐C, LDL‐C, TG and GA concentrations, with an automatic anal‐
yser	(LABOSPECT	008;	Hitachi).	Serum	insulin	concentrations	were	
measured by chemiluminescence immunoassay using an automatic 
analyser (AIA‐2000 LA; Tosoh). Plasma glucose concentrations were 
measured using a hexokinase method, and HbA1c levels were mea‐




We divided the subjects with NGT into four groups (I‐IV), based upon 
the time (30, 60, or 120 minutes or never) and showed the sequen‐
tial changes in plasma glucose (Figure 1A) and insulin (Figure 1B) at 
which	their	plasma	glucose	concentration	during	the	OGTT	declined	
below the fasting glucose concentration, following a published pro‐
tocol.5 Groups I, II and III included subjects whose plasma glucose 




We calculated areas under the glucose or insulin curves (AUCg and 
AUCi) based on the trapezoid rule. We also calculated the homeo‐
stasis	 model	 assessment	 of	 insulin	 resistance	 (HOMA‐IR,	 fasting	
plasma glucose [PG0] (mg/dL) × IRI0 (μU/mL)/405),13 β‐cell function 
(HOMA‐β, IRI0 (μU/mL)	×	360/[PG0	(mg/dL)	−	63])13 and Matsuda 
index of insulin sensitivity (10,000/square root of [fasting glucose 
(mg/dL) × fasting insulin (μU/mL)] × [mean glucose (mg/dL) × mean 
insulin (μU/mL)	 during	 OGTT]),14 as reported. We calculated the 
insulinogenic index by dividing the increment in serum insulin (μU/
mL) by the increment in plasma glucose (mg/dL) during the 0‐ to 30‐
minutes	 time	periods	of	 the	OGTT.15 The insulin secretion/insulin 
resistance (disposition) index was calculated as insulinogenic index 
x Matsuda index.16
The	SPSS	version	25	 statistical	 software	package	was	used	 to	
perform the statistical analyses. The data were expressed as the 
mean ± standard deviation. We compared the continuous variables 
across	the	glucose	tolerance	groups	using	one‐way	ANOVA	followed	
by	Tukey's	post	hoc	tests.	We	used	ROC	curves	to	discriminate	be‐
tween group II and group III + IV by some indices.
3  | RESULTS
3.1 | Clinical characteristics
The average age of the 575 NGT subjects was 23.7 ± 1.7 years, and 
the average BMI was 21.2 kg/m2	 (Table	 1).	Of	 these,	 28	 subjects	
(4.9%), 120 subjects (20.9%), 143 subjects (24.9%), and 284 sub‐




Figure 1 and Table 2 show the sequential changes in plasma glucose 
and	insulin	for	each	group	during	OGTT.	We	observed	significant	dif‐
ferences among the groups, especially in the plasma glucose values. 
The 30‐minute postload plasma glucose (PG30) in group II was sig‐
nificantly higher than that in group I, and that in groups III and group 
IV was significantly higher than that in groups I and II. Regarding the 
60‐minute postload plasma glucose (PG60), the values in groups III 
and IV were significantly higher than those in groups I and II. The 
mean level of the 120‐minute postload plasma glucose (PG120) in 
group IV was significantly higher than that in the other groups.
Regarding plasma insulin, we observed no significant differences 
in the fasting plasma insulin (IRI0) among groups. For the mean 30‐
minute postload plasma insulin (IRI30), those in groups II, III and 
IV were significantly higher than the average in group I. The mean 
60‐minute postload plasma insulin (IRI60) was significantly higher in 
groups III and IV than in groups I and II. The mean 120‐minute post‐
load plasma insulin (IRI120) of group IV was significantly higher than 
that in the other groups. Although we divided subjects according 
TA B L E  1   Clinical characteristics of the NGT subjects
Gender
Male, 359; Female, 
216
Age 23.7 ± 1.7 y
Height 167.7 ± 8.3 cm
Weight 59.6 ± 10.4 kg
BMI 21.1 ± 2.5
FPG 90.5 ± 6.7 mg/dL
(5.03 ± 0.37 mmol/L)
FPI 6.5 ± 3.4 IU/L
HbA1c	(NGSP) 5.29 ± 0.2%
GA 13.4 ± 1.1%
CPR 1.42 ± 0.76 ng/mL
Data	presented	as	mean	±	SD.	Abbreviations:	CPR,	C‐peptide	immuno‐
reactivity; FPG, fasting plasma glucose; FPI, fasting plasma insulin; GA, 
glycoalbumin.
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to the shape of glucose concentration curve,5 insulin concentration 
curve showed a similar shape.
3.3 | Lipid profiles
In the analyses of lipid profiles, the HDL‐C levels in groups III and IV 
were significantly lower than those in group II. The LDL‐C levels in 
group IV were significantly higher than those in group III, and we found 
no significant differences in the TG levels among the groups (Table 2).
3.4 | AUC of glucose and insulin
The incremental areas under both the glucose and insulin curves 
(AUCg and AUCi) increased progressively from groups II to IV 
(Table 2). In contrast, we found no significant differences in the ratio 
of AUCi/AUCg among the groups.
3.5 | Glucose metabolism indices
We found no significant differences in the HbA1c levels among 
groups.	 Likewise,	 the	 mean	 insulin	 resistance	 index,	 HOMA‐IR	
showed	no	significant	group	differences.	Similarly,	there	were	no	
significant	differences	 in	mean	HOMA‐β and indicator of insulin 
secretion potential. However, the Matsuda index, an indicator of 
whole‐body insulin sensitivity, declined progressively from group 
I to IV, and the insulinogenic index, calculated by (IRI30‐IRI0)/
(PG30‐PG0), was less than 0 in group I, a higher value in group II, 
a lower value in group III and an even lower value in group IV. The 
TA B L E  2   Baseline and metabolic characteristics of the NGT subjects
 I II III IV
n 28 (4.9%) 120 (20.9%) 143 (24.9%) 284 (49.4%)
Male:female 10:18 64:56 102:41**  185:99** 
BMI (kg/m2) 20.2 ± 2.1 20.5 ± 2.1 21.1 ± 2.3 21.3 ± 2.8
PG0 (mg/dL) 89.6 ± 6.7 90.2 ± 6.1 92.5 ± 6.8 89.6 ± 6.5§§ 
IRI0 (μU/mL) 7.0 ± 3.7 6.5 ± 2.8 6.5 ± 3.3 6.4 ± 3.6
HbA1c	(%)	(NGSP) 5.29 ± 0.14 5.29 ± 0.19 5.30 ± 0.20 5.28 ± 0.22
GA (%) 13.5 ± 1.1 13.4 ± 0.89 13.3 ± 1.2 13.4 ± 1.0
PG30 (mg/dL) 80.1 ± 11.16 117.9 ± 16.4**  135 ± 22.5**,++  139.5 ± 22.0**,++ 
PG60 (mg/dL) 87.6 ± 21.4 81.3 ± 10.9 116.8 ± 20.1**,++  127.6 ± 26.5**,++,§ 
PG120 (mg/dL) 79.6 ± 11.9 85.0 ± 14.8 82.1 ± 10.8 106.7 ± 12.8**,++,§§ 
IRI30 (μU/mL) 36.8 ± 21.0 66.8 ± 49.2**  57.1 ± 52.0**  55.0 ± 30.5* 
IRI60 (μU/mL) 30.7 ± 21.1 29.0 ± 15.6 52.1 ± 34.0**,++  51.9 ± 30.8**,++ 
IRI120 (μU/mL) 26.8 ± 12.6 28.4 ± 18.7 26.2 ± 15.8 43.1 ± 27.5**,++,§§ 
HDL‐C (mg/dL) 68.1 ± 10.8 66.5 ± 12.8 62.6 ± 14.7+  62.3 ± 10.1++ 
LDL‐C (mg/dL) 93.6 ± 22.4 95.5 ± 21.3 95.1 ± 24.4 102.5 ± 27.1§ 
TG (mg/dL) 67.3 ± 23.9 67.3 ± 29.2 74.4 ± 36.3 77.1 ± 41.6
AUCg 10 080 ± 1460 11 100 ± 1120 13 150 ± 1580**,++  14 470 ± 1870**,++,§§ 
AUCi 3450 ± 1510 4270 ± 2160 5330 ± 3110**,+  5500 ± 2780**,++ 
AUCi/AUCg 0.342 ± 0.137 0.385 ± 0.195 0.402 ± 0.217 0.380 ± 0.182
HOMA‐IR 1.54 ± 0.89 1.53 ± 1.03 1.50 ± 0.82 1.42 ± 0.93
HOMA‐β 95.7 ± 40.6 87.4 ± 34.9 80.5 ± 39.3 88.1 ± 43.9
Insulinogenic index –3.34 ± 3.19 2.17 ± 2.17**  1.43 ± 3.38**,++  0.84 ± 1.27**,++ 
Matsuda index 8.18 ± 3.34 6.94 ± 2.78 6.28 ± 2.90*  5.86 ± 2.98**,++ 
Disposition index –28.14 ± 27.28 15.68 ± 16.35**  7.97 ± 15.70**,++  4.92 ± 9.03**,++,§§ 
Data	presented	as	mean	±	SD.	Abbreviations:	BMI,	body	mass	index;	GA,	glycoalbumin;	HDL‐C,	high‐density	lipoprotein	cholesterol;	HOMA‐IR,	
homeostasis	model	assessment	of	insulin	resistance;	HOMA‐β, homeostasis model assessment of beta cell function; IRI0, fasting plasma insulin; 
IRI30, 30‐min postload plasmas insulin; IRI60, 60‐min postload plasmas insulin; IRI120, 120‐min postload plasma insulin; PG0, fasting plasma glucose; 
PG30, 30‐min postload plasma glucose; LDL‐C = low‐density lipoprotein cholesterol; PG60, 60‐min postload plasma glucose; PG120, 120‐min post‐
load plasma glucose; TG, triglyceride.
*P < .05 vs group I. 
+P < .05 vs group II. 
§P < .05 vs group III. 
**P < .01 vs group I. 
++P < .01 vs group II. 
§§P < .01 vs group III. 
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disposition index (the product of Matsuda index and insulinogenic 
index), reflected the combination of insulin secretion and insulin 
sensitivity, also showed a similar trend (less than 0 in group I, the 




In the past study, Abdul‐Ghani et al defined group I + II as low‐risk 
group for T2DM, and group III + IV as high‐risk group for T2DM.5 
Low‐risk group showed rapid glucose lowering, and high‐risk group 
showed prolonged glucose elevation. Therefore, we described 
ROC	 curves	 of	 indices	 between	 groups	 identifying	 the	 high‐risk	
group (group III + IV) from the low‐risk group (group I + II). The 
Matsuda, insulinogenic and disposition indices were compared. 
Between	groups	 I	 +	 II	 and	 III	 +	 IV,	 the	AUCs	of	ROC	of	 the	dis‐
position, the insulinogenic and Matsuda indices were not good 
(AUC	 =	 0.706,	 0.652	 and	 0.629,	 respectively)	 (Figure	 2A).	 Since	
PG30 is smaller than PG0 in group I, insulinogenic and disposition 
indices were calculated into negative value in group I. Negative 
value misled to be poor insulin secretion potential. Therefore, we 
excluded	the	group	 I	 from	ROC	analysis.	As	a	result,	good	AUCs	
were obtained in disposition index (AUC = 0.847) better than the 
insulinogenic and Matsuda indices (AUC = 0.786, 0.616, respec‐
tively; Figure 2B).
4  | DISCUSSION
In this cross‐sectional study, we found that healthy young Japanese 
individuals within physiological range of glycaemic control accompa‐
nied the sequential decreases in insulin sensitivity and secretion. We 
showed	the	differences	in	the	OGTT‐derived	indices	of	insulin	sensi‐
tivity and insulin secretion among 4 groups, according to a previous 
study.5 The insulin sensitivity, calculated using the Matsuda index, de‐
creased progressively in subjects from groups I to IV as with the study.5 
In addition, the insulin secretion assessed using the insulinogenic index 
decreased in the subjects from groups II to IV (the value of this index in 
group I was less than zero by definition) along with the study.5
Although we tried to classify participants by insulin secretion 
pattern according to the previous study,17 we could not find a signif‐
icant difference among groups. We also tried to apply other indices 
such as the QUICKI (quantitative insulin sensitivity check index),18 
the McAuley (an index of insulin resistance)19 and the fasting Belfiore 
(fasting insulin resistance index)20; however, we found no significant 
differences between the groups (data not shown).
In terms of glucose tolerance, our results showed similar insulin 
sensitivities or secretion levels to the levels in the above‐mentioned 
study.11 Even though the mean age of subjects in our study at 23.7 
was 30 years younger than the mean age of subjects in the prior study 
at 54.1,5 our results suggest that Japanese young individuals and 
Finnish middle‐aged individuals share similar glucose metabolism. 
This is similar to a publication, suggesting that the insulin response 
in Asian Americans was lower than that in other ethnic groups such 
as Hispanic American, Caucasians and African Americans.21
Among	the	Japanese	population,	a	study	on	OGTTs	among	2157	
middle‐aged Japanese individuals showed that only 1125 (52.1%) 
had NGT, while the others had IFG (525 [24.3%]), IGT (159 [7.3%]), 
IFG + IGT (263 [12.2%]) and diabetes (85 [3.9%]).22 The mean age of 
that study was 52.6 years, which was similar to that in the study by 
Abdul‐Ghani et al5,22 Young normoglycaemic children of Indian par‐
ents with diabetes mellitus showed higher plasma insulin levels, and 
lower insulin sensitivity and β‐cell compensation than subjects with‐
out parents with T2DM.23 The difference may have been caused by 
the different ethnicities, dietary habits or family histories.
F I G U R E  2  Summary	of	ROC	curve	analysis	for	disposition	
index, insulinogenic index and Matsuda index for groups I + II 
and III + IV (A) and groups II and III + IV (B). A, Disposition index: 
AUC, 0.706; CI, 0.645‐0.768. Insulinogenic index: AUC, 0.652; 
CI, 0.590‐0.714. Matsuda index: AUC, 0.629; CI, 0.579‐0.679. 
(B) Disposition index: AUC, 0.847; CI, 0.814‐0.881. Insulinogenic 
index: AUC, 0.786; CI, 0.738‐0.834. Matsuda index: AUC, 0.616; CI, 
0.562‐0.669
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The IRI0, an index that can identify the future risk for T2DM, 
has been associated with insulin resistance. A comparison between 
the	OGTT	and	the	euglycaemic	hyperinsulinaemic	clamp	technique	
suggested that the fasting insulin level should be a marker of insulin 
resistance.24 In addition, an insulin suppression test study concluded 
that	fasting	plasma	insulin	and	HOMA‐IR	were	highly	correlated	in	
nondiabetic individuals.25 However, in the present study, we found 
no significant difference in IRI0 among the study groups.
Some	 subjects	 showed	 lower	 glucose	 values	 at	 PG30	 than	 at	
PG0. In addition, about 5% of the subjects in group I had negative in‐
sulinogenic index values, a percentage close to that in the literature, 
where the majority of individuals with low glucose and increased in‐
sulin values belonged to the NGT group.26 In the present study, all 
the subjects in group I showed similar changes in glucose and insulin. 
Although	we	tried	to	draw	the	ROC	curves	classifying	the	prolonged	
glucose elevation group (group III + IV) from the rapid glucose low‐
ering group (group I + II), the specificities of insulinogenic and dispo‐
sition indices were poor (Figure 2A). These results were explained 
as follows: they were calculated into negative value in group I. In 
general, a higher insulinogenic index shows better insulin secretion. 
Although subjects in group I were thought to have good insulin se‐
cretion potential, negative value misled to be poor insulin secretion 
potential.	Therefore,	we	excluded	the	group	I	from	ROC	analysis.	As	
a result, good AUCs were obtained in disposition index (Figure 2B).
Among the glucose and insulin indices, the most significant dif‐
ferences were observed in the AUCg among the groups. However, 
this was an inevitable result given that we divided the subjects into 
four groups according to their glucose values.
The definition of the disposition index varies among the re‐
searchers. While Weiss et al determined it as the product of the insu‐
linogenic index and the Matsuda index,16 Asano et al calculated it as 
the	quotient	of	the	insulinogenic	index	divided	by	the	HOMA‐IR,27 
and Retnakaran et al calculated it as the product of the Matsuda 
index and the AUCi/AUCg.28 We used the product of the insulino‐
genic index and the Matsuda index because we found no significant 
differences	in	HOMA‐IR	and	AUCi/AUCg,	among	the	study	groups.	
Our	analyses	with	the	AUCi/AUCg	x	Matsuda	index	showed	differ‐
ences among groups similar to those of the Matsuda index alone 
(data not shown). For the product of the insulinogenic index and the 
Matsuda index, we found more significant differences among groups 
than insulinogenic index as with the study by Abdul‐Ghani et al.5
We	compared	the	ROC	curves	of	indices	between	groups	distin‐
guishing the prolonged glucose elevation group (group III + IV) from 
the rapid glucose lowering group (group II). Between group II and 
group	III	+	IV,	disposition	index	showed	good	AUC	of	ROC	compared	
to insulinogenic and Matsuda indices (Figure 2B). The Matsuda index 
is a good indicator of whole‐body insulin sensitivity.14	On	the	other	
hand, in Japanese, IGT is associated with reduction of insulin secre‐
tion.29 These data suggested low early secretion of insulin has larger 
impact on glucose intolerance of Japanese than low peripheral in‐
sulin sensitivity. Further, disposition index, an index that indicates 
the composition of insulin secretion and sensitivity, may be a good 
indicator of glucose tolerance.
T2DM and its complications account for more than 2 million 
deaths every year, and they impose substantial economic costs on 
patients, on their families and on health systems.30 The direct annual 
cost of diabetes in the world is estimated at $825 billion, with China 
($170	billion),	the	USA	($105	billion),	India	($73	billion)	and	Japan	($37	
billion) having the largest costs.30 In the present study, about three 
fourths of young Japanese subjects within physiological range of gly‐
caemic control accompanied sequential decreases in insulin sensitivity 
and secretion. Previous report showed that Japanese have lower in‐
sulin secretion potential than Caucasians.31 Furthermore, prevalence 
of T2DM among Asian Americans is higher than Caucasians.32 The 
National	Health	and	Nutrition	Survey	by	Ministry	of	Health,	Labour	
and Welfare reported that fat intake of Japanese is increasing. The in‐
sulin resistance is expected to increase as previous study stated.33 To 
reduce the economic burden of T2DM, it seems important to identify 
those at high‐risk and to promote lifestyle habit improvements for the 
prevention of macrovascular diseases. Although this study showed no 
significant	difference	in	HOMA‐IR	and	HOMA‐β among young healthy 
Japanese individuals, subjects with decreased insulin sensitivity and 
secretion	could	be	found	by	75gOGTT	and	disposition	index.
There are some limitations in our study. First, we did not take fa‐
milial T2DM history into consideration, and individuals with affected 
parents	should	not	have	participated	in	the	study.	Second,	we	did	not	
account for food intake and exercise habits, especially the behaviour 
of previous day, and these may affect insulin sensitivity or secretion. 
Third, the omission of the 90‐min value might have also compro‐
mised the accuracy of our estimates of the Matsuda index, the AUCg 
and the AUCi. Real glucose shape (monophasic or biphasic) was not 
assessed either. Fourth, this study is a pure cross‐sectional study and 
only provides indirect evidence of an increased risk for the develop‐
ment	of	type	2	diabetes	mellitus.	Fifth,	participants	took	OGTT	only	
one time. Therefore, intraindividual variability was not assessed.
In conclusion, even in a young and healthy Japanese individual 
within the physiological range of glucose control, there is a sequen‐
tial	 decrease	 in	 insulin	 sensitivity	 and	 secretion.	 So	 that,	 the	 pro‐
motion of lifestyle habit improvements for prevention of T2DM is 
needed for young Japanese. Further study is needed to investigate 
the familial history, food and exercise habit, activity former to the 
study and 90‐minute value, and follow‐up study will make clear the 
glucose metabolism and future risk of T2DM among young Japanese.
CONFLICT OF INTEREST
There are no conflicts of interest to declare.
AUTHORS’  CONTRIBUTIONS
TK	and	MM	designed	the	study.	OA,	TO,	KT,	YS,	HI	and	MN	have	
contributed to data collection. AY contributed to data interpreta‐
tion and wrote the initial draft of the manuscript. TK contributed to 
analysis and interpretation of data, and assisted in the preparation 
of the manuscript. MM critically reviewed the manuscript and finally 
approved of the article. All authors approved the final version of the 
     |  7 of 7ISHIGAKI et Al.
manuscript and agreed to be accountable for all aspects of the work 
in ensuring that questions related to the accuracy or integrity of any 
part of the work are appropriately investigated and resolved.
ORCID
Akihiro Yoshida  https://orcid.org/0000‐0001‐7224‐6550 
REFERENCES
	 1.	 Wei	M,	Gaskill	SP,	Haffner	SM,	Stern	MP.	Effects	of	diabetes	and	
level of glycemia on all‐caused and cardiovascular mortality. The 
San	Antonio	Heart	Study.	Diabetes Care. 1998;21:1167‐1172.
 2. Khaw KT, Wareham N, Luben R, et al. Glycated haemoglobin, di‐
abetes, and mortality in men in Norfolk cohort of European pro‐
spective investigation of cancer and nutrition (EPIC‐Norfolk). BMJ. 
2001;322:15‐18.
	 3.	 Tominaga	M,	Eguchi	H,	Manaka	H,	 Igarashi	K,	Kato	TA,	Sekikawa	
A. Impaired glucose tolerance is a risk factor for cardiovascular 
disease, but not impaired fasting glucose. The Funagata Diabetes 
Study.	Diabetes Care. 1999;22:920‐924.
 4. Abdul‐Ghani MA, Tripathy D, DeFronzo RA. Contributions of beta‐
cell dysfunction and insulin resistance to the pathogenesis of im‐
paired glucose tolerance and impaired fasting glucose. Diabetes 
Care. 2006;29:1130‐1139.
 5. Abdul‐Ghani MA, Lyssenko V, Tuomi T, DeFronzo RA, Groop L. 
The	 shape	 of	 plasma	 glucose	 concentration	 curve	 during	 OGTT	





 7. Charles MA, Fontbonne A, Thibult N, Warnet JM, Rosselin GE, 
Eschwege E. Risk factors for NIDDM in white population. Paris pro-
spective study. Diabetes. 1991;40:796‐799.
	 8.	 Vaccaro	O,	Ruffa	G,	Imperatore	G,	Iovino	V,	Rivellese	AA,	Riccardi	
G. Risk of diabetes in the new diagnostic category of impaired 
fasting glucose: a prospective analysis. Diabetes Care. 1999;22: 
1490‐1493.
	 9.	 Vaccaro	O,	Ruffa	G,	Imperatore	G,	Iovino	V,	Rivellese	AA,	Riccardi	
G. The 1997 American Diabetes Association and 1999 World 
Health	Organization	criteria	for	hyperglycemia	in	the	diagnosis	and	
prediction of diabetes. Diabetes Care. 2000;23:1108‐1112.
 10. de Vegt F, Dekker JM, Jager A, et al. Relation of impaired fasting and 
postload glucose with incident type 2 diabetes in a Dutch popula‐
tion:	the	Hoorn	Study.	JAMA. 2001;285:2109‐2113.
	11.	 Unwin	N,	Shaw	J,	Zimmet	P,	Alberti	KG.	Impaired	glucose	tolerance	
and impaired fasting glycaemia: the current status on definition and 
intervention. Diabet Med. 2002;19:708‐723.
	12.	 American	 Diabetes	 Association.	 Standards	 of	 Medical	 Care	 in	
Diabetes—2010. Diabetes Care.	2010;33:S11‐S61.
	13.	 Matthews	DR,	Hosker	 JP,	 Rudenski	 AS,	Naylor	 BA,	 Treacher	DF,	
Turner RC. Homeostasis model assessment: insulin resistance and 
beta‐cell function from fasting plasma glucose and insulin concen‐
trations in man. Diabetologia. 1985;28:412‐419.
 14. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from 
oral glucose tolerance testing: comparison with the euglycemic in‐
sulin clamp. Diabetes Care. 1999;22:1462‐1470.
 15. Kosaka K, Kuzuya T, Yoshinaga H, Hagura R. A prospective study 
of health check examinees for the development of non‐insulin‐de‐
pendent diabetes mellitus: relationship of the incidence of diabetes 






Fujimoto	WY.	Patterns	of	 insulin	 concentration	during	 the	OGTT	
predict the risk of type 2 diabetes in Japanese Americans. Diabetes 
Care. 2013;36(5):1229‐1235.
	18.	 Chen	H,	 Sullivan	G,	Yue	 LQ,	Katz	A,	Quon	MJ.	QUICKI	 is	 a	 use‐
ful index of insulin sensitivity in subjects with hypertension. Am J 
Physiol Endocrinol Metab. 2003;24:460‐464.
	19.	 McAuley	KA,	Williams	SM,	Mann	JI,	et	al.	Diagnosing	insulin	resis‐
tance in the general population. Diabetes Care. 2001;24:460‐464.
	20.	 Belfiore	F,	Iannello	S,	Volpicelli	G.	Insulin	sensitivity	indices	calcu‐
lated	from	basal	and	OGTT‐induced	insulin,	glucose,	and	FFA	levels.	
Molo Genet Metab. 1998;63:134‐141.
	21.	 Jensen	 CC,	 Cnop	M,	 Hull	 RL,	 Fujimoto	WY,	 Kahn	 SE.	 American	
Diabetes	Association	GENNID	Study	Group.	Beta‐cell	function	is	a	
major contributor to oral glucose tolerance in high‐risk relatives of 
four	ethnic	groups	in	the	U.S.	Diabetes. 2002;51:2170‐2178.
	22.	 Oka	R,	Yagi	K,	Sakurai	M,	et	al.	 Insulin	 secretion	and	 insulin	 sen‐
sitivity	 on	 the	oral	 glucose	 tolerance	 test	 (OGTT)	 in	middle‐aged	
Japanese. Endocrine. 2012;59:55‐64.
	23.	 Praveen	EP,	Sahoo	J,	Khurana	ML,	et	al.	 Insulin	sensitivity	and	β‐
cell function in normoglycemic offspring of individuals with type 2 
diabetes mellitus: Impact of line of inheritance. Indian J Endocrinol 
Metab. 2016;16:105‐111.
 24. Laakso M. How good a marker is insulin level for insulin resistance? 
Am J Epidemiol. 1993;137:959‐965.
	25.	 Abbasi	 F,	Okeke	Q,	 Reaven	GM.	 Evaluation	 of	 fasting	 plasma	 in‐
sulin concentration as an estimate of insulin action in nondiabetic 
individuals: comparison with the homeostasis model assessment of 
insulin	resistance	(HOMA‐IR).	Acta Diabetol. 2014;51:193‐197.
	26.	 Kahn	 SE,	 Lachin	 JM,	 Zinman	 B,	 et	 al.	 Effects	 of	 Rosiglitazone,	
Glyburide, and Metformin on β‐Cell	Function	and	Insulin	Sensitivity	
in	ADOPT.	Diabetes. 2011;60:1552‐1560.
	27.	 Asano	T,	Yoshida	R,	Ogata	H,	 et	 al.	Glucose	disposition	 in	 obese	
Japanese students. Endocrine. 2007;54:903‐910.
	28.	 Retnakaran	R,	Shen	S,	Hanley	AJ,	Vuksan	V,	Hamilton	JK,	Zinman	
B. Hyperbolic relationship between insulin secretion and sensitivity 
on oral glucose. Obesity. 2008;16:1901‐1907.
 29. Heianza Y, Arase Y, Fujihara K, et al. High normal HbA(1c) levels 
were associated with impaired insulin secretion without escalating 
insulin resistance in Japanese individuals: the Toranomon Hospital 
Health	 Management	 Center	 Study	 8	 (TOPICS	 8).	 Diabet Med. 
2012;29(10):1285‐1290.
 30. NCD Risk Factor Collaboration. Worldwide trends in diabetes since 
1980: a pooled analysis of 751 population‐based studies with 4·4 
million participants. Lancet 2016;387(10027):1513‐1530.
	31.	 Ahuja	V,	Kadowaki	T,	Evans	RW,	et	 al.	Comparison	of	HOMA‐IR,	
HOMA‐β%	 and	 disposition	 index	 between	 US	 white	 men	 and	
Japanese men in Japan: the ERA. Diabetologia. 2015;58(2):265‐271.




dietary fat intake and insulin resistance in Chinese child twins. Br J 
Nutr. 2017;117(2):230‐236.
How to cite this article:	Ishigaki	H,	Yoshida	A,	Araki	O,	et	al.	
Prolonged plasma glucose elevation on oral glucose tolerance 
test in young healthy Japanese individuals. Endocrinol Diab 
Metab. 2020;3:e00098. https ://doi.org/10.1002/edm2.98
